In Vitro Antimicrobial Activity And Clinical Evaluation of Therapeutic Effects of Cefotetan (YM09330) on Respiratory Tract Infections

Akira Watanabe, Seiichi Aonuma, Kikuo Onuma, Kotaro Oizumi, Kiyoshi Konno, Masako Sasaki

    Research output: Contribution to journalArticlepeer-review

    1 Citation (Scopus)


    In vitro antimicrobial activity of cefotetan (CTT, YM09330), a new derivative of cephamycin, was examined by a broth dilution method with Dynatech MIC 2000 system. Also, therapeutic efficacy of cefotetan in the treatment of patients with respiratory tract infections was evaluated. The minimum inhibitory concentrations (MICs) of cefotetan, cefazolin, cefotiam and cefmetazole against following 328 strains of clinical isolates were compared: 53 strains of S. aureus, 79 strains of E. coli, 100 strains of K. pneumoniae, 55 strains of Enterobacter sp., five strains of Citrobacter sp., seven strains of H. alvei and 29 strains of S. marcescens. It was revealed that cefotetan was more highly active against gram-negative rods, such as E. coli, K. pneumoniae, Enterobacter sp., Citrobacter sp. and S. marcescens, and more weakly active against S. aureus than cefazolin, cefotiam and cefmetazole. Cefotetan was almost as active as cefotiam and cefmetazole against H. alvei. A daily dose of 2 grams of cefotetan was given to a total of 12 patients by an intravenous drip infusion. The subjects examined consisted of one patient with acute bronchitis, two patients with acute pneumonia, one patient with lung abscess associated with diabetes mellitus, two patients with infection associated with bronchiectasis, one patient with chronic bronchitis and five patients with infection associated with lung cancer. Clinical response to the treatment with cefotetan was excellent in three, good in six and fairly good in two patients, and poor in one patient. Following eight potential pathogens were recovered from the sputum of these patients at the start of the treatment with cefotetan, one strain of S. aureus, three strains of H. influenzae, two strains each of K. pneumoniae and E. cloacae. All of them were eradicated during the treatment with cefotetan. An elevation of slight degree of serum transaminase was observed in two patients and eosinophilia in one patient. These abnormal findings returned to normal after cessation of cefotetan. From the above results, it was concluded that cefotetan is one of the most effective and useful antibiotics against gram-negative bacterial infections in compromised hosts.

    Original languageEnglish
    Pages (from-to)346-361
    Number of pages16
    Publication statusPublished - 1982 Jan 1

    ASJC Scopus subject areas

    • Pharmacology (medical)
    • Infectious Diseases
    • Pharmacology
    • Drug Discovery
    • Oncology


    Dive into the research topics of 'In Vitro Antimicrobial Activity And Clinical Evaluation of Therapeutic Effects of Cefotetan (YM09330) on Respiratory Tract Infections'. Together they form a unique fingerprint.

    Cite this